Published in Eur J Cancer on July 14, 2008
Assessment of Breast Specimens With or Without Calcifications in Diagnosing Malignant and Atypia for Mammographic Breast Microcalcifications Without Mass: A STARD-Compliant Diagnostic Accuracy Article. Medicine (Baltimore) (2015) 0.91
First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat (2016) 0.85
Improving work-up of the abnormal mammogram through organized assessment: results from the ontario breast screening program. J Oncol Pract (2012) 0.82
Needle core biopsy for screen detected breast lesions: time to raise the bar? Eur J Cancer (2008) 0.75
[Diagnostics of microcalcifications from minimally invasive biopsies in mammography screening: results from the prevalence phase]. Pathologe (2009) 0.75
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
Prognostic markers in triple-negative breast cancer. Cancer (2007) 6.28
Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol (2011) 6.13
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84
Basal-like breast cancer: a critical review. J Clin Oncol (2008) 5.64
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol (2004) 3.80
Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75
Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol (2007) 3.55
Validating whole slide imaging for diagnostic purposes in pathology: guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med (2013) 3.39
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol (2010) 3.27
Review of the current state of whole slide imaging in pathology. J Pathol Inform (2011) 3.23
Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol (2007) 3.12
Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia (2006) 3.08
High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer (2005) 3.07
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res (2009) 2.91
Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget (2010) 2.64
Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med (2011) 2.49
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol (2010) 2.42
Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol (2007) 2.33
Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res (2010) 2.33
Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet (2006) 2.23
A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol (2006) 2.17
Triple-negative/basal-like breast cancer: review. Pathology (2009) 2.17
Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res (2006) 2.16
Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol (2008) 2.13
ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med (2011) 2.07
Further evidence that E-cadherin is not a tumour suppressor gene in invasive ductal carcinoma of the breast: an immunohistochemical study. Histopathology (2013) 2.05
Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol (2005) 2.03
Regulation of endocytosis via the oxygen-sensing pathway. Nat Med (2009) 2.00
High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol (2007) 2.00
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging (2009) 1.88
Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol (2013) 1.83
Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol (2005) 1.82
IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res (2008) 1.80
The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol (2010) 1.79
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res (2007) 1.78
Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol (2009) 1.77
Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer (2006) 1.76
Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol (2005) 1.70
Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res (2009) 1.63
Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol (2010) 1.63
Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res (2008) 1.58
Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. J Urol (2008) 1.53
Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer (2006) 1.52
The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer. Mol Med (2007) 1.51
The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer (2007) 1.49
Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer (2007) 1.46
Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat (2010) 1.43
Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res (2009) 1.42
Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol (2008) 1.41
Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol (2008) 1.40
Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat (2007) 1.39
Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol (2007) 1.38
Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features. Radiology (2010) 1.36
Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival. AJR Am J Roentgenol (2007) 1.34
Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat (2008) 1.33
LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Res Treat (2011) 1.33
BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. Cancer Res (2007) 1.33
An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat (2010) 1.31
Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma. FASEB J (2005) 1.30
Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res (2007) 1.29
Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology (2007) 1.29
Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers. Radiology (2008) 1.28
The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification. Breast Cancer Res (2003) 1.27
The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer (2011) 1.27
The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat (2009) 1.27
Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. Breast (2012) 1.27
An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. Hum Pathol (2003) 1.26
PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol (2012) 1.26
Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer (2005) 1.25
Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer (2008) 1.24
Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. Am J Surg Pathol (2003) 1.24
CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat (2007) 1.22
Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int J Cancer (2006) 1.20
Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res (2009) 1.18
A CD44⁻/CD24⁺ phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res Treat (2011) 1.15
Implications of pathologist concordance for breast cancer assessments in mammography screening from age 40 years. Hum Pathol (2002) 1.13
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res (2012) 1.13
Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology (2010) 1.13
Loss of Dicer expression is associated with breast cancer progression and recurrence. Breast Cancer Res Treat (2012) 1.12
MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat (2010) 1.12